Ipravent Inhaler

Ipratropium bromide, the active ingredient in Ipravent Inhaler, is an anticholinergic (muscarinic antagonist) presented as a metered‑dose inhaler for inhalation use. It treats chronic obstructive pulmonary disease and asthma, providing maintenance bronchodilation in adult patients. It is indicated for long‑term maintenance therapy and can be used as part of combination treatment regimens.

GNH USA supplies Ipravent Inhaler as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Ipratropium bromide is a bronchodilator that acts on the airways to relieve obstruction in chronic respiratory diseases. - Chronic Obstructive Pulmonary Disease (COPD): improves airflow and reduces breathlessness in stable disease. - Asthma (adjunct therapy): enhances symptom control when added to inhaled corticosteroids or β2‑agonists. - Chronic bronchitis: decreases sputum production and eases breathing difficulty.

Ipratropium bromide may cause a range of adverse reactions, most of which are mild and related to its anticholinergic activity.

Common Side Effects: - Dry mouth: sensation of oral dryness after inhalation. - Cough: transient irritation leading to coughing. - Throat irritation: discomfort or soreness in the throat. - Headache: mild headache reported by some users. - Dizziness: occasional light‑headedness. - Taste alteration: unusual taste sensation after use.

Serious or Rare Side Effects: - Paradoxical bronchospasm: sudden worsening of breathing requiring medical attention. - Allergic reactions: rash, urticaria, or angioedema. - Urinary retention: difficulty emptying the bladder, especially in predisposed individuals. - Narrow‑angle glaucoma exacerbation: increased intra‑ocular pressure. - Severe tachycardia: rapid heart rate that may need intervention.

Before prescribing Ipratropium bromide, clinicians should evaluate patient history and monitor for specific safety concerns. - Assess respiratory status: confirm diagnosis and severity of airway obstruction. - Monitor anticholinergic effects: watch for dry mouth, urinary retention, or visual disturbances. - Caution in glaucoma: avoid use in patients with narrow‑angle glaucoma. - Avoid in hypersensitivity: do not use if the patient has known allergy to ipratropium or atropine derivatives. - Pregnancy and lactation: safety not established; weigh potential benefits against risks. - Store at room temperature: keep inhaler in original packaging, protect from moisture and heat.

Ipratropium bromide can interact with other medications, influencing anticholinergic load or cardiovascular response.

Major Interactions (Avoid): - Other anticholinergic agents: may increase anticholinergic side‑effects such as dry mouth and urinary retention. - Beta‑agonists: combined use can lead to additive cardiovascular effects, requiring monitoring. - MAO inhibitors: risk of hypertensive crisis when used together.

Moderate Interactions (Monitor Closely): - Theophylline: may heighten risk of tachyarrhythmias. - Diuretics: can potentiate urinary retention. - Antihistamines: may enhance anticholinergic adverse effects.